MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584854 | Name: Nifekalant

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nifekalant is a potassium channel blocker.

Chemical Structure

Nifekalant
CAS#130636-43-0

Theoretical Analysis

MedKoo Cat#: 584854

Name: Nifekalant

CAS#: 130636-43-0

Chemical Formula: C19H27N5O5

Exact Mass: 405.2012

Molecular Weight: 405.46

Elemental Analysis: C, 56.28; H, 6.71; N, 17.27; O, 19.73

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Nifekalant
IUPAC/Chemical Name
6-((2-((2-hydroxyethyl)(3-(p-nitrophenyl)propyl)amino)ethyl)amino)-1,3-dimethyl-uracil
InChi Key
InChI=1S/C19H27N5O5/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29/h5-8,14,20,25H,3-4,9-13H2,1-2H3
InChi Code
InChI=1S/C19H27N5O5/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29/h5-8,14,20,25H,3-4,9-13H2,1-2H3
SMILES Code
O=C(N1C)N(C)C(NCCN(CCO)CCCC2=CC=C([N+]([O-])=O)C=C2)=CC1=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 405.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Otuki S, Hasegawa K, Watanabe H, Katsuumi G, Yagihara N, Iijima K, Sato A, Izumi D, Furushima H, Chinushi M, Aizawa Y, Minamino T. The effects of pure potassium channel blocker nifekalant and sodium channel blocker mexiletine on malignant ventricular tachyarrhythmias. J Electrocardiol. 2017 May - Jun;50(3):277-281. doi: 10.1016/j.jelectrocard.2016.09.005. Epub 2016 Sep 8. PubMed PMID: 28238302. 2: Tagami T, Matsui H, Ishinokami S, Oyanagi M, Kitahashi A, Fukuda R, Unemoto K, Fushimi K, Yasunaga H. Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest. Resuscitation. 2016 Dec;109:127-132. doi: 10.1016/j.resuscitation.2016.08.017. Epub 2016 Aug 24. PubMed PMID: 27568110. 3: Harayama N, Nihei S, Nagata K, Aibara K, Kamochi M, Sata T. [Drug Therapy for Shock-Resistant Ventricular Fibrillation: Comparison of Nifekalant and Amiodarone]. J UOEH. 2016 Mar 1;38(1):35-46. doi: 10.7888/juoeh.38.35. Review. Japanese. PubMed PMID: 26972943. 4: Ishizaka T, Yoshimatsu Y, Maeda Y, Chiba K, Mori K. Negative lusitropic property of nifekalant identified using ventricular pressure-volume loop analyses in anesthetized monkeys. Exp Anim. 2019 Feb 26;68(1):91-102. doi: 10.1538/expanim.18-0098. Epub 2018 Oct 17. PubMed PMID: 30333366; PubMed Central PMCID: PMC6389513. 5: Karlis G, Iacovidou N, Lelovas P, Niforopoulou P, Papalois A, Siafaka I, Mentzelopoulos S, Xanthos T. Nifekalant Versus Amiodarone in the Treatment of Cardiac Arrest: an Experimental Study in a Swine Model of Prolonged Ventricular Fibrillation. Cardiovasc Drugs Ther. 2015;29(5):425-31. doi: 10.1007/s10557-015-6604-7. PubMed PMID: 26145169. 6: Sato S, Zamami Y, Imai T, Tanaka S, Koyama T, Niimura T, Chuma M, Koga T, Takechi K, Kurata Y, Kondo Y, Izawa-Ishizawa Y, Sendo T, Nakura H, Ishizawa K. Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia. Sci Rep. 2017 Oct 4;7(1):12683. doi: 10.1038/s41598-017-13073-0. PubMed PMID: 28978927; PubMed Central PMCID: PMC5627292. 7: Harayama N, Nihei S, Nagata K, Isa Y, Goto K, Aibara K, Kamochi M, Sata T. Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation. J Anesth. 2014 Aug;28(4):587-92. doi: 10.1007/s00540-013-1775-5. Epub 2014 Jan 5. PubMed PMID: 24389941; PubMed Central PMCID: PMC4126999. 8: Yamabe H, Tanaka Y, Morihisa K, Uemura T, Koyama J, Kanazawa H, Hoshiyama T, Ogawa H. Electrophysiologic mechanism of typical atrial flutter termination by nifekalant: effect of a pure IKr -selective blocking agent. Pacing Clin Electrophysiol. 2013 Sep;36(9):1123-31. doi: 10.1111/pace.12147. Epub 2013 Apr 22. PubMed PMID: 23607491. 9: Ichiki T, Wada M, Yasukouchi Y, Nakahara T, Mitoma C, Uchi H, Nishizaki A, Mukai Y, Furue M. Crystallization granuloma by nifekalant hydrochloride infusion. Geriatr Gerontol Int. 2018 Jul;18(7):1133-1134. doi: 10.1111/ggi.13329. PubMed PMID: 30133966. 10: Pantazopoulos IN, Troupis GT, Pantazopoulos CN, Xanthos TT. Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias. World J Cardiol. 2011 Jun 26;3(6):169-76. doi: 10.4330/wjc.v3.i6.169. PubMed PMID: 21772943; PubMed Central PMCID: PMC3139038. 11: Kawaji T, Shizuta S, Yamagami S, Aizawa T, Komasa A, Yoshizawa T, Kato M, Yokomatsu T, Miki S, Ono K, Kimura T. Clinical Utility of Intravenous Nifekalant Injection during Radiofrequency catheter Ablation for Persistent Atrial Fibrillation. J Atr Fibrillation. 2018 Jun 30;11(1):1839. doi: 10.4022/jafib.1839. eCollection 2018 Jun-Jul. PubMed PMID: 30455835; PubMed Central PMCID: PMC6207242. 12: Zhou Y, Liu XM, Wang L, Jiang XH. An HPLC method for the determination of nifekalant hydrochloride in canine plasma and its application to a pharmacokinetic study. J Chromatogr Sci. 2013 Oct;51(9):867-71. doi: 10.1093/chromsci/bms182. Epub 2012 Nov 20. PubMed PMID: 23169932. 13: Karlis G, Afantenou S. Drugs in cardiac arrest: the rise and fall of antiarrhythmics. Acta Cardiol. 2018 Aug;73(4):325-327. doi: 10.1080/00015385.2017.1389803. Epub 2017 Oct 12. PubMed PMID: 29025372. 14: Aoki H, Suzuki T, Matsui H, Yasukochi S, Saiki H, Senzaki H, Nakamura Y. Efficacy of a pure Ikr blockade with nifekalant in refractory neonatal congenital junctional ectopic tachycardia and careful attention to damaging the atrioventricular conduction during the radiofrequency catheter ablation in infancy. HeartRhythm Case Rep. 2017 Mar 29;3(6):298-301. doi: 10.1016/j.hrcr.2017.03.005. eCollection 2017 Jun. PubMed PMID: 28649501; PubMed Central PMCID: PMC5469282. 15: Ji XF, Li CS, Wang S, Yang L, Cong LH. Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest. Resuscitation. 2010 Aug;81(8):1031-6. doi: 10.1016/j.resuscitation.2010.04.023. Epub 2010 Jun 2. PubMed PMID: 20627529. 16: Watanabe H, Chinushi M, Washizuka T, Sugiura H, Hirono T, Aizawa Y, Komura S, Hosaka Y, Tanabe Y, Furushima H, Aizawa Y. Comparison of efficacy of sotalol and nifekalant for ventricular tachyarrhythmias. Circ J. 2006 May;70(5):583-7. PubMed PMID: 16636494. 17: Kumagai K, Toyama H. Usefulness of ablation of complex fractionated atrial electrograms using nifekalant in persistent atrial fibrillation. J Cardiol. 2013 Jan;61(1):44-8. doi: 10.1016/j.jjcc.2012.08.015. Epub 2012 Oct 22. PubMed PMID: 23088936. 18: Tang M, Zhang S, Sun Q, Hua W, Huang CX. Effect of nifekalant on acute electrical remodelling in rapid atrial pacing canine model. Chin Med J (Engl). 2006 Dec 20;119(24):2056-61. PubMed PMID: 17199956. 19: Zhang M, Shi G, Sui Y, An Y, Yan M, Tang Y. The application of an LC-MS/MS method in a pharmacokinetic study for the determination of the concentration of nifekalant in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Nov 1;938:105-10. doi: 10.1016/j.jchromb.2013.09.003. Epub 2013 Sep 7. PubMed PMID: 24076524. 20: Sonoda K, Watanabe I, Ohkubo K, Okumura Y, Kofune M, Sasaki N, Kogawa R, Mano H, Nakai T, Hirayama A. Rate-dependent electrophysiologic effects of the class III antiarrhythmic drugs nifekalant, amiodarone, and ibutilide on the atrium in patients with persistent atrial fibrillation. Int Heart J. 2013;54(5):279-84. PubMed PMID: 24097216.